How to Get Repatha (Evolocumab) in California

What Is Repatha and Why California Patients Need a Clear Path to Access

Repatha is a monoclonal antibody that blocks proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that degrades LDL receptors on liver cells. Blocking PCSK9 keeps more LDL receptors active, which lowers circulating LDL-C by roughly 59% on top of background statin therapy. The FDA approved evolocumab in August 2015 for adults with heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), and established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering beyond diet and maximally tolerated statin therapy. 1

California has roughly 39.5 million residents, and familial hypercholesterolemia affects approximately 1 in 250 people in the general population, meaning an estimated 158,000 Californians may have HeFH. 2 Many are undiagnosed. The state's large geography and provider shortage in inland counties make telehealth prescribing especially relevant.

The landmark FOURIER trial (N=27,564) showed that adding evolocumab to statin therapy reduced LDL-C by a mean of 59% and cut the composite of cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization by 15% (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) over a median follow-up of 2.2 years. 3 That degree of risk reduction is the clinical foundation underlying why California payers and prescribers treat access to PCSK9 inhibitors as a genuine medical priority rather than a lifestyle preference.

Step 1: Confirm You Qualify for a Repatha Prescription in California

FDA labeling and most California payer policies align on two primary qualifying diagnoses. Qualifying takes roughly one office visit.

Heterozygous or homozygous familial hypercholesterolemia. HeFH is diagnosed using the Dutch Lipid Clinic Network (DLCN) criteria or a genetic test confirming a pathogenic LDLR, APOB, or PCSK9 variant. A DLCN score of 6 to 8 indicates probable HeFH; a score of 9 or above indicates definite HeFH. 4 HoFH requires confirmed biallelic mutations or an untreated LDL-C above 500 mg/dL with clinical features.

Established ASCVD. The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction defines established ASCVD as prior acute coronary syndrome, myocardial infarction, stable angina, coronary or other arterial revascularization, stroke, TIA, or peripheral arterial disease presumed to be of atherosclerotic origin. 5 Patients in this category with LDL-C remaining at or above 70 mg/dL on maximally tolerated statin therapy are candidates for evolocumab under the guideline.

Most California commercial payers also require documentation that the patient has tried at least one high-intensity statin (atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg) for a minimum of 90 days, or has a documented intolerance with a muscle enzyme or hepatic panel confirming the rationale for stopping. 6

Step 2: Get the Right Labs Before Your Appointment

A fasting lipid panel is the single most important pre-prescription lab. You need it done before the first visit.

Your prescriber will need a fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides), a comprehensive metabolic panel (CMP) covering hepatic function and renal function, and a creatine kinase (CK) level if statin myopathy has been a concern. 7 Labs drawn within 90 days are generally acceptable to both the prescriber and the insurance company completing the prior authorization. If you have a prior lipid panel from your primary care doctor, bring a copy or have records forwarded before the appointment to avoid repeating bloodwork.

For patients pursuing the familial hypercholesterolemia pathway, genetic testing through a CLIA-certified laboratory adds supporting documentation that can accelerate prior authorization. Quest Diagnostics and LabCorp both operate CLIA-certified California draw sites and can process LDLR mutation panels. Results typically return in 10 to 21 days.

Thyroid function (TSH) is worth adding if your LDL elevation has not been fully explained by genetics or diet, because hypothyroidism is a reversible secondary cause that payers may require you to rule out before approving a PCSK9 inhibitor.

Step 3: Find a Prescriber in California (In-Person or Telehealth)

California law permits telehealth prescribing for non-controlled medications after a valid patient-provider relationship is established. Evolocumab is not a controlled substance.

In-person options. A board-certified cardiologist, lipidologist, or internist can prescribe Repatha during a standard office visit. University of California health systems (UCSF, UCLA, UC San Diego, UC Davis) each maintain dedicated lipid clinics staffed by preventive cardiologists with experience managing PCSK9 inhibitor therapy and navigating prior authorizations. Wait times at academic centers run eight to twelve weeks for new patients in major California cities.

Telehealth options. California Business and Professions Code section 2290.5 explicitly authorizes prescribing via synchronous audio-video telehealth after the provider establishes an appropriate clinical relationship. 8 HealthRX and similar telehealth platforms licensed in California can evaluate you via video visit, review uploaded lab results, and transmit an electronic prescription to a California-licensed pharmacy. Telehealth appointments are often available within two to five business days versus weeks at in-person cardiology practices.

Who can prescribe in California. Licensed physicians (MD/DO), nurse practitioners (NP) holding a California furnishing number, and physician assistants (PA) authorized under a practice agreement can all prescribe evolocumab in California. 9 Nurse practitioners in California operate under full practice authority as of January 2023 for NPs who meet the transition-to-practice requirements under AB 890, meaning NP-led telehealth visits carry full prescribing authority for medications like Repatha without a collaborative physician agreement in most settings. 10

Step 4: Manage Prior Authorization for Repatha in California

Prior authorization (PA) is nearly universal for evolocumab across California payers. The PA process is the step most likely to delay access.

Commercial insurers operating in California, including Anthem Blue Cross, Blue Shield of California, Kaiser Permanente, and Health Net, each publish evolocumab PA criteria that mirror the ACC/AHA guideline thresholds. Most require: (a) a qualifying diagnosis (HeFH by DLCN criteria or genetic test, HoFH, or established ASCVD); (b) current LDL-C documented above the threshold (typically 70 mg/dL for ASCVD, 100 mg/dL for HeFH without ASCVD); (c) proof of an adequate statin trial or documented intolerance; and (d) prescriber attestation that the patient is receiving lifestyle counseling. 11

Medi-Cal (California Medicaid). Medi-Cal covers evolocumab for HeFH and established ASCVD with PA under the Drug Utilization Review process. The Drug Effectiveness Review Project and ICER reviews that informed Medi-Cal policy found evolocumab cost-effective at approximately $5,850 per year at net price versus list price. 12 Medi-Cal PA approvals typically take 3 to 7 business days for standard review or 72 hours for expedited review when a prescriber documents urgent clinical need.

Amgen's PCSK9 patient support programs. Amgen offers the Repatha SupportPlus program, which provides PA assistance, co-pay cards for commercially insured patients (reducing out-of-pocket cost to as low as $5 per month for eligible patients), and a free 30-day starter supply pending PA approval. Contact Amgen at 1-844-REPATHA to enroll before your prescription is transmitted to the pharmacy. 13

Appeals. California Health & Safety Code section 1368 gives patients the right to an independent medical review (IMR) through the California Department of Managed Health Care (DMHC) when a PA is denied. The DMHC IMR process has overturned PCSK9 inhibitor denials where the clinical documentation met guideline criteria. 14 If your prescriber submits a complete PA with lipid values, statin trial documentation, and a DLCN score or genetic result, denials are uncommon.

Step 5: Fill Your Prescription at a California Pharmacy

Repatha ships cold (2 to 8 degrees Celsius) and is dispensed through retail specialty pharmacies and mail-order specialty pharmacy networks.

Specialty pharmacy networks. CVS Specialty, Walgreens Specialty, and Accredo (part of Evernorth) are the most common specialty pharmacy channels used by California-licensed prescribers. These pharmacies handle benefit verification, PA coordination, and cold-chain shipping directly to your California address. 15

503A compounding pharmacies. California-licensed 503A compounding pharmacies are permitted by the California State Board of Pharmacy to compound patient-specific formulations of biologic analogs under specific conditions, but the branded Repatha product from Amgen is not compoundable in the traditional 503A sense because evolocumab is a large-molecule monoclonal antibody produced by recombinant DNA in CHO cells. No 503A pharmacy in California (or elsewhere) compounds evolocumab itself. What 503A pharmacies in California can dispense is branded Repatha if they are licensed as a non-resident pharmacy or a retail pharmacy with appropriate cold-chain handling. 16 Confirm your pharmacy holds an active California license at the California State Board of Pharmacy license lookup before transferring a prescription.

Transferring an out-of-state Repatha prescription to California. If you move to California or establish care with a new California provider, a Repatha prescription written in another state can be transferred to a California-licensed pharmacy. Repatha is not a controlled substance, so federal and California pharmacy law permit one transfer from one licensed pharmacy to another. The receiving California pharmacy must verify the original prescription is valid and has remaining refills. Your new California prescriber can also write a fresh prescription, which is the faster path if your out-of-state prescriber is no longer active in your care.

Expected timeline from prescription to first injection. After a PA approval, specialty pharmacies typically ship within one to two business days. Cold-chain shipments within California arrive in one to three business days via overnight or two-day carrier. Total time from a new patient appointment to first dose ranges from two weeks (telehealth with rapid PA approval) to six weeks (in-person referral with a standard PA process).

The Clinical Evidence Behind Prescribing Evolocumab

Clinicians and payers both reference a short list of landmark trials when evaluating PCSK9 inhibitor therapy. The evidence base is strong and specific.

FOURIER (2017, N=27,564). Published in the New England Journal of Medicine, FOURIER randomized patients with established ASCVD and LDL-C at or above 70 mg/dL on optimized statin therapy to evolocumab or placebo. Mean LDL-C fell from 92 mg/dL to 30 mg/dL in the evolocumab group, a 59% reduction. The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, coronary revascularization) occurred in 9.8% of the evolocumab group vs. 11.3% placebo (HR 0.85, P<0.001). 3 The trial enrolled over 1,000 patients from US sites, including California academic centers.

GLAGOV (2016, N=968). GLAGOV used intravascular ultrasound to measure coronary atherosclerosis progression. Evolocumab produced a mean LDL-C of 36.6 mg/dL and a mean percent atheroma volume change of -0.95% versus +0.05% for placebo (P<0.001), providing imaging evidence that evolocumab can actually regress established plaque. 17

HAUSER-RCT (2020, N=300). This trial specifically evaluated HoFH patients. Evolocumab reduced LDL-C by 30.9% vs. placebo in patients already on statins, ezetimibe, and LDL apheresis in some cases. 18 The result supported FDA approval for HoFH and is directly cited in Medi-Cal PA criteria.

The ACC/AHA 2022 Guideline on Cardiovascular Risk Reduction assigns a Class I, Level A recommendation to PCSK9 inhibitor therapy for patients with very high ASCVD risk whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe. 5 "For patients with very high-risk ASCVD, a PCSK9 inhibitor is recommended if LDL-C remains at or above 70 mg/dL despite maximally tolerated statin and ezetimibe therapy," states the guideline writing committee.

Safety, Side Effects, and Monitoring After Starting Repatha

Evolocumab has a favorable safety profile across more than five years of follow-up data.

Injection-site reactions occur in about 2.1% of patients in FOURIER. Nasopharyngitis, upper respiratory tract infection, and flu-like symptoms each occurred in fewer than 10% of patients and were similar to placebo rates. 3 There is no clinically significant hepatotoxicity signal, no CK elevation pattern, and no increase in new-onset diabetes compared with placebo, which distinguishes evolocumab from high-intensity statins in that respect. 19

Cognitive safety was examined in the EBBINGHAUS sub-study (N=1,204), which found no difference in cognitive function between evolocumab and placebo groups over 19 months of follow-up, addressing early theoretical concerns about very low LDL and brain function. 20

After starting Repatha, a fasting lipid panel at 4 to 12 weeks confirms LDL-C response. A 50% or greater reduction from baseline confirms adequate absorption and compliance. If LDL-C does not fall by at least 30%, the prescriber should assess injection technique and confirm the drug was stored correctly at 2 to 8 degrees Celsius. 21 Ongoing lipid monitoring every 6 to 12 months is standard once the patient reaches the LDL-C target.

HealthRX Clinical Perspective: A Decision Framework for California Patients

The following framework is used by the HealthRX medical team to sequence steps for California patients requesting evolocumab. It reflects the clinical and administrative realities specific to California payers and pharmacy networks.

Tier 1: Established ASCVD, LDL-C <70 mg/dL on high-intensity statin plus ezetimibe. These patients meet the ACC/AHA Class I threshold. Book a telehealth visit with a California-licensed HealthRX provider. Upload a fasting lipid panel drawn within 90 days and documentation of your current statin and ezetimibe doses. The prescriber will submit PA on the same day or next business day after the visit. Most commercial insurers approve within 5 to 7 business days.

Tier 2: HeFH, DLCN score of 6 or above, LDL-C above 100 mg/dL on statin. If you have a genetic result or DLCN documentation, bring it. If not, the HealthRX provider can apply the DLCN criteria during the telehealth visit using your personal and family history plus your current LDL-C. Genetic testing can proceed in parallel; PA is often approvable on clinical criteria alone for DLCN scores of 9 or above.

Tier 3: Statin-intolerant patients. You need a CK level and a hepatic panel documenting the reason for statin discontinuation. Without that, the PA will likely be denied on first submission. A bempedoic acid trial of 90 days may be required by some California payers before PCSK9 inhibitor approval in statin-intolerant patients without ASCVD. 22

Tier 4: Medi-Cal patients. The process is identical but routed through the Medi-Cal Drug Utilization Review. Allow 5 to 10 business days. If denied, a peer-to-peer review call between the HealthRX prescriber and the Medi-Cal medical director resolves most clinically appropriate cases.

Dosing, Injection Technique, and Storage in California's Climate

Repatha comes in two presentations: a 140 mg/mL single-use prefilled autoinjector (SureClick) and a 420 mg/3.5 mL prefilled cartridge for use with the on-body infusor. 1

The standard adult dose is 140 mg subcutaneously every two weeks or 420 mg once monthly. Both regimens produce equivalent LDL-C reduction at steady state. Monthly dosing improves adherence in patients who prefer fewer injections. 23

For injection, rotate sites among the abdomen, upper arm, and thigh. Inject at room temperature after removing the autoinjector from the refrigerator 30 minutes before use. Do not inject into areas that are bruised, tender, or scarred. The autoinjector delivers the full dose in approximately 15 seconds.

California's summer temperatures in inland counties (Sacramento Valley, Coachella Valley, Inland Empire) exceed 40 degrees Celsius. Repatha stored outside the refrigerator must be used within 30 days and must not exceed 25 degrees Celsius. 1 Patients in hot climates should request insulated shipping from the specialty pharmacy and store pens immediately on arrival. A 140 mg dose pen that has been exposed to temperatures above 25 degrees Celsius for more than 30 days should be discarded and a replacement requested through the specialty pharmacy.

Cost and Financial Assistance for California Patients

The list price of Repatha is approximately $700 per monthly dose (420 mg) as of early 2025, making financial assistance programs clinically relevant for patients without specialty drug coverage. 24

Amgen's Repatha SupportPlus co-pay card reduces out-of-pocket cost to as low as $5 per month for commercially insured, Medicare-ineligible California patients. Patients on Medicare Part D who meet the low-income subsidy criteria may also qualify for additional cost-sharing reductions under the Inflation Reduction Act drug price negotiation provisions that took effect for certain drugs in 2026. 25

California's Medi-Cal program, when PA is approved, covers evolocumab with standard Medi-Cal cost-sharing, which is zero co-pay for most full-scope Medi-Cal beneficiaries. Covered California marketplace plans are required under the ACA preventive services mandate to cover PCSK9 inhibitors without cost-sharing when prescribed for FDA-approved indications after the US Preventive Services Task Force's cardiovascular risk reduction recommendations. 26